The purpose of this clinical trial is to see if the drug Finerenone is safe and effective in patients with in participants with non-diabetic chronic kidney disease. Additionally, while finerenone has been approved for other patient populations, this study will collect additional safety information about finerenone to determine how it affects the body.
Inclusion Criteria
- History of organ transplantation
- Established diagnosis of Type 1 or 2 Diabetes mellitus
If you aren't sure you qualify, please call us and we will help determine your eligibility
Exclusion Criteria
Study Requirements
If you qualify, you will receive either the study drug finerenone or placebo for 32-49 months. We will then follow up with you for 1 month. Visit frequency is approximately every 1-4 months.
